Stockreport

Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study [Yahoo! Finance]

Lyra Therapeutics, Inc.  (LYRA) 
PDF Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting WATERTOWN, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) [Read more]